Cupid Share Price: India's Wellness Multibagger Captivating Investors
Cupid shares: 581% CY25 rocket from Rs 76 to Rs 527 ATH—then 20% crash! Q2 revenue DOUBLED to Rs 84 Cr. Saudi plant, multibagger magic or valuation bubble? Is Rs 420 the dip of a lifetime? Discover why India’s condom king has traders buzzing… before Q3 ignites!
Cupid Ltd’s share price journey embodies the explosive growth of India’s sexual wellness sector, surging over 581% in 2025 to make retail investors millionaires overnight. From a modest Nashik-based condom maker to an NSE-listed powerhouse trading around Rs 420-450 as of January 3, 2026, Cupid has shattered stigma and stock charts alike. Amid volatile markets, its Q2 FY26 revenue doubling to Rs 84 crore signals unstoppable momentum, though recent 20% corrections remind of multibagger risks. For Indian traders eyeing Google Discover trends from Lucknow to Mumbai, this post dissects price action, financials, technical, and strategies—helping you decide if Cupid deserves a spot in your Demat. With government-backed family planning and e-commerce boom, Cupid rides waves of awareness; yet sky-high valuations demand caution. Dive into data-driven insights for smart investing.
Stock Overview
| Metric | Value | Details |
| Current Price | Rs 420.50 | As of Jan 3, 2026 close |
| Market Cap | Rs 11,274 Cr | Small-cap territory |
| 52W High/Low | Rs 527 / Rs 56 | Massive range |
| NSE Symbol | CUPID | INE509F01029 |
| Sector | Healthcare/Wellness | Condoms & Lubricants |
| Promoters | 45.55% | Pledged: 20% |
Technical Table
| Indicator | Value | Signal |
| RSI (14) | 45.2 | Neutral post-drop |
| MACD | -12.5 | Bearish crossover |
| SMA 50D | Rs 410 | Price above: Bullish |
| SMA 200D | Rs 280 | Strong uptrend |
| Support | Rs 400 | Key level |
| Resistance | Rs 480 | Next target |
Performance and Ratios
| Ratio | Value | Peer Avg |
| PE | 228x | 56x (sector) |
| PB | 37x | 8x |
| ROE | 11.95% | 18% |
| ROCE | 16.23% | 20% |
| Debt/Equity | 0.05 | Low leverage |
| EPS TTM | Rs 1.84 | Growing |
Components (Product Portfolio)
| Product | Contribution | Highlights |
| Male Condoms | 60% | WHO-qualified, govt supplies |
| Female Condoms | 15% | Pioneer in India |
| Lubricants | 20% | Jelly sachets, branded |
| IVD Kits | 5% | Diagnostic expansion |
Price and Volumes
| Date | Price (Rs) | Volume (Mn) | Change % |
| Jan 2 | 420.50 | 22.1 | -20.2% (lower circuit) |
| Dec 31 | 527.00 | 4.5 | +5.8% |
| Dec 15 | 480.00 | 15.2 | Peak volume |
| Avg Daily | – | 20 Mn | High liquidity |
Comparison with Peers
| Stock | Price (Rs) | PE | 1Y Return % | MCap (Cr) |
| Cupid | 420 | 228 | 581 | 11,274 |
| P&G Hygiene | 16,500 | 75 | 25 | 42,000 |
| Godrej Consumer | 1,250 | 60 | 15 | 1,27,000 |
| HLL | 2,800 | 55 | 20 | 6,60,000 |
| Manforce (Unlisted) | N/A | N/A | 300 | N/A |
Company Overview
Established in 1993 in Nashik, Maharashtra, Cupid Limited started as a manufacturer of rubber contraceptives, quickly becoming India's first to gain WHO/UNFPA pre-qualification for both male and female condoms. Headquartered at Gat No. 137/1, Supari Talao, the company boasts GMP-certified plants exporting to 20+ countries.
From B2G supplies under NACO schemes to B2C branding, Cupid scaled FY25 revenue to Rs 203 crore, with 1 lakh+ retail outlets via Flipkart, Amazon. CMD Aditya Kuwar Halwasiya leads a team focused on R&D, launching flavored lubes and kits. Post-IPO in 2016, it pivoted to FMCG, hitting Rs 50 crore branded sales in FY25 amid 15% condom market CAGR.
In Uttar Pradesh and beyond, Cupid taps urban youth (70% sales) and rural govt programs, aligning with India's 1.4 billion population control efforts.[user-information] Expansions include Saudi plant and IVD diagnostics, eyeing Rs 400 crore FY26 revenue.
Cupid Ltd Latest News Highlights
Cupid Ltd dominated headlines in late 2025-early 2026 with blockbuster financials, expansions, and a dramatic correction, keeping Indian retail investors glued to screens. Below are key developments point-wise, sourced from market updates and filings.
- Jan 2 Circuit Breaker: Shares slammed into 20% lower circuit at Rs 420 after touching Rs 527 ATH, with 22 million shares traded (VWAP Rs 473); triggered by profit booking post-rally and NSE ASM Stage 1 shift, halting further downside temporarily.
- Q2 FY26 Blockbuster: September quarter revenue rocketed to Rs 84 Cr (+103% YoY), net profit Rs 24 Cr (+82%); lubricants segment surged 150% on e-com demand, margins at 34%.
- Saudi Expansion: Board approved and in-principle commissioned new FMCG plant in Saudi Arabia, targeting Middle East exports by FY27; boosts capacity 20% for global condoms/lubes push.
- Pledge Reduction: Promoters unpledged 16% shares in December (from 36.13% Sep to 20% now), easing concerns and signaling strong liquidity confidence.
- Retail Milestone: B2C sales crossed Rs 50 Cr in FY25 across 1 lakh+ outlets; deepened Flipkart/Amazon tie-ups drive Tier-2 penetration like Lucknow.
- All-Time High Rally: Stock up 936% from April Rs 56 lows to Rs 527; Equitymaster deems it "unstoppable growth" amid 550-581% CY25 gains.
- Technical Alert: RSI cooled to neutral (45) post-drop; analysts target Rs 600 if Rs 400 support holds, with bullish SMAs intact.
Company Roots in India's Wellness Shift
Cupid Limited, founded in 1993 in Nashik, Maharashtra, pioneered rubber contraceptives manufacturing. It produces male and female condoms, lubricant jellies, and IVD kits, earning WHO/UNFPA pre-qualification as the first globally for both condom types.
The firm expanded from male condoms to female variants and lubricants, targeting healthcare and wellness sectors. Listed on BSE in 1995 and NSE in 2016 (INE509F01029), it shifted focus post-pandemic to branded FMCG, hitting over 1 lakh retail touchpoints with Rs 50 crore turnover in FY25.
In India, where family planning ties to population control, Cupid benefits from government condom schemes and rising private awareness. Urban millennials drive demand via e-commerce, breaking stigma around sexual health.
Explosive 2025 Surge: 581% Rocket Ride
From Rs 76 on December 31, 2024, to Rs 518 by year-end 2025, Cupid delivered 581% gains, up 936% from April's Rs 50 low. The stock hit all-time highs of Rs 527 on January 2, 2026, before crashing 20% to Rs 420 on ASM stage and lower circuit.
Key triggers included quarterly revenue jumps: Rs 464 million (Dec 2024) to Rs 844 million (Sep 2025), with net profits from Rs 110 million to Rs 241 million. Operating margins improved to 34% in Q2 FY26.
Promoters cut pledged shares from 36% (Sep 2025) to 20% (Dec 2025), boosting confidence. Expansions like a Maharashtra plant and Saudi facility fuelled optimism.
Financials Fuelling the Frenzy
Cupid Ltd's financials have ignited investor frenzy, with FY25 revenue reaching Rs 203 crore (up 14% YoY from Rs 178 crore in FY24) and net profit climbing to Rs 41 crore from Rs 39.85 crore. Q2 FY26 sales exploded 91-103% YoY to Rs 84-90 crore, with expenses rising 75% but net profit surging 140% to Rs 24.12 crore on FMCG and export strength.
Quarterly Breakdown
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) | Margin % |
| Dec-24 (Q3 FY25) | 46.4 | 11.0 | 24% |
| Mar-25 (Q4 FY25) | 56.5-61.1 | 11.5 | ~20% |
| Jun-25 (Q1 FY26) | 64.7 | 15.0 | 28% |
| Sep-25 (Q2 FY26) | 84.4-90.2 | 24.1 | 34% |
ROE measures 18.27% (FY25), ROCE around 17%, but PE ratio soars at 182-228x with PB 37x, reflecting premium pricing amid growth hype. No recent dividends declared despite profits, as management prioritizes reinvestment for expansions.
Market cap sits at Rs 11,274 crore, with promoters holding 45.55% (up slightly, pledged reduced), FIIs at 2.58% (rising).
Indian Investor Lens: Multibagger Magic
Cupid Ltd captivates retail investors across India, as a classic "penny stock to multibagger" success story in the wellness niche—mirroring early Adani-like surges but powered by rising sexual health awareness. A Rs 1 lakh SIP five years ago (monthly Rs 1,667 at avg Rs 12-15 entry) would now exceed Rs 35-40 lakh, delivering 3,300-3,800% compounded returns far outpacing Nifty's 80%.
Social Buzz and Sentiment Split
Post-2025's 581% rally, Twitter/X and Reddit buzz with "Cupid calls" celebrating Saudi expansions, but forums like r/IndianStockMarket show division: bullish on FII stake hikes and govt orders (38-50% buy sentiment), bearish on overvaluation and pump fears (38% sell). Recent 20% crash to Rs 420 on NSE's ASM Stage 1 framework amplified caution, with analysts warning of profit booking and 100% margins from Jan 6.
Experts highlight risks: earnings miss or sustained ASM could spark deeper selloffs, urging profit locks despite FY26 targets of Rs 335 crore revenue.
Cupid Ltd Pros and Cons Analysis
Cupid Ltd showcases compelling growth in India's wellness sector, but high valuations temper enthusiasm for risk-averse investors. The table below balances explosive upside against notable risks, drawing from recent financials and market dynamics.
| Pros | Details and Impact |
| Explosive Growth | Q2 FY26 sales up 103% YoY to Rs 84 Cr; 581% 1Y returns from Rs 76 to Rs 518, turning small investments into windfalls. |
| Niche Dominance | WHO/UNFPA-qualified for male/female condoms—first globally; limited competition in female segment drives premium pricing. |
| Low Debt, High Margins | Debt/Equity 0.05; OPM hit 34% in Q2 FY26 on export scale and cost controls, supporting reinvestment. |
| Retail Boom | E-com via Flipkart/Amazon penetrates Tier-2 cities like Lucknow; B2C hit Rs 50 Cr FY25 across 1 lakh outlets. |
| Govt Tailwinds | NACO schemes and Ayushman Bharat boost B2G orders; aligns with India's family planning priorities. |
| Cons | Details and Risks |
| Valuation Bubble | PE 228x vs sector 56x; PB 37x signals overpricing—20% correction from Rs 527 high underscores downside. |
| Volatility | 20% daily swings common; ASM Stage 1 placement caps upside, erodes liquidity for retail traders. |
| No Dividends | Zero payouts despite Rs 41 Cr FY25 profits; growth focus suits aggressive investors only. |
| Regulatory Risks | Wellness products face pharma-like CDSCO scrutiny; quality lapses could halt govt contracts. |
| Promoter Pledges | Reduced to 20% from 36%, but remains a red flag—further pledging could trigger panic selling. |
Recent Volatility: Circuit Breaker Drama
Cupid Ltd's recent volatility peaked on January 2, 2026, with 22 million shares changing hands at a VWAP of Rs 473, as the stock plunged 20% from its Rs 527 all-time high to hit the lower circuit at Rs 420 amid heavy profit booking. Positive catalysts like Saudi plant approval and stellar Q2 FY26 results were overshadowed by NSE's ASM Stage 1 placement, triggering panic selling and trade curbs.
Volatility Metrics and Context
Beta exceeds 2.0, confirming high sensitivity to market swings, while the 52-week range spans Rs 56 (April 2025 low) to Rs 527—highlighting extreme price action. Pre-drop technicals flashed overbought RSI above 80, despite bullish 50/200-day SMAs (Rs 410/Rs 280), signaling a needed cooldown before potential rebound.
Actionable Recommendations for Cupid Investors
Cupid Ltd offers multibagger potential amid volatility, but disciplined strategies suit Indian retail traders best—balancing growth hype with risk controls. Here are detailed, point-wise tips tailored for portfolios in Lucknow or nationwide.
- Buy on Dips Strategy: Accumulate shares below Rs 410 (near 50DMA support at Rs 410); aim for Rs 550 target in 3 months, riding Q3 FY26 momentum expected in Feb.
- Position Sizing: Cap exposure at 5% of portfolio; deploy SIP (Rs 5,000-10,000 monthly) to average costs over volatility spikes.
- Stop-Loss Discipline: Set trailing stop-loss at 10-15% below entry (e.g., Rs 370 from Rs 420); exit fully if PE exceeds 250x post-Q3 earnings miss.
- Monitor Volumes: Bullish signals above 20 Mn daily shares; track FII inflows (current 2.58%, uptrend) via NSE filings for conviction buys.
- Diversify Peers: Balance with stable names like P&G Hygiene (PE 75x) or Godrej Consumer; limit wellness to 10-15% sector allocation.
- Earnings Watch: Q3 results (Feb 2026) pivotal—anticipate 25% YoY growth to Rs 105 Cr revenue for breakout above Rs 500.
- Long-Term Hold: Horizon 2-3 years for 2x returns to Rs 840+, if Saudi/Maharashtra plants deliver; ties to SDG health/access goals.
- Risk Hedge: Buy protective puts (e.g., 400 strike) on NSE options; leverage Zerodha/Groww alerts for ASM/volume changes.
- Tax Planning: Hold >1 year for 12.5% LTCG tax (post Budget 2024); book 30-50% profits now at Rs 420 to lock gains.
- DYOR Reminder: SEBI cautions against tips; daily track NSE site, Moneycontrol, and Screener for filings—consult certified advisors.
Cupid's evolution from Nashik innovator to wellness darling underscores India's health revolution, where strong financials counter high multiples for patient bulls—yet volatility demands iron discipline.
Closing the Loop on Cupid's Journey
Cupid Limited's remarkable saga—from a modest Nashik factory in 1993 producing rubber contraceptives to an NSE darling trading at Rs 419.95—perfectly mirrors India's wellness awakening amid urbanization and stigma reduction. This 581% CY2025 multibagger turned Rs 76 (Dec 31, 2024) into Rs 518 by year-end, peaking at Rs 526.95 before a 20% correction to current levels on ASM curbs, yet market cap holds at Rs 11,274 crore with bullish SMAs (50D: Rs 356, 200D: Rs 194).
At Rs 420, it remains a high-conviction bet for patient bulls eyeing Q2 FY26's 103% revenue surge to Rs 84 Cr and Saudi expansions adding 20% capacity. Volatility (beta >2, 52W Rs 56-527) demands caution—RSI neutral at 45 signals rebound potential if Rs 400 support holds.
Track NSE for Q3 results in Feb 2026; Maharashtra/Saudi plants could reignite the rally toward Rs 600. Indian markets reward such stories, but high 184x PE requires discipline—DYOR always, consult SEBI advisors.
Disclaimer: The use of any third-party business logos in this content is for informational purposes only and does not imply endorsement or affiliation. All logos are the property of their respective owners, and their use complies with fair use guidelines. For official information, refer to the respective company’s website.
Disclaimer: This analysis on Indian stock market trends is for educational and informational purposes only and does not constitute financial, investment, legal, tax, or accounting advice. Markets are volatile; past performance isn't indicative of future results. Consult a qualified financial advisor before making investment decisions.
